Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma

By: Meg Barbor, MPH
Posted: Monday, October 9, 2017

The ratio of absolute lymphocyte count (ALC) to absolute monocyte count (AMC) in the peripheral blood appears to serve as a prognostic immune biomarker in newly diagnosed patients with multiple myeloma and may reflect the immunologic status of these patients, wrote Talib Dosani, MD, of Case Western Reserve University/University Hospitals Cleveland Medical Center, and colleagues, in the Blood Cancer Journal.

“Our study is novel in that we show that the ALC/AMC is a more robust prognostic biomarker than ALC alone, as it assesses the relative strength of the host immune system to myeloma-induced immune dysfunction,” the investigators reported.

The retrospective study included 372 patients diagnosed with multiple myeloma between 2004 and 2014. After a median follow-up of 37.5 months, patients with baseline ALC/AMC ≥ 3.6 (N=236) versus ALC/AMC < 3.6 (N=136) experienced longer median progression-free (43 months vs. 24 months, respectively) and median overall survival (62 months vs. 48 months, respectively).

The clinical implications of these findings indicate the ALC/AMC may help to stratify patients based on their baseline immune status. The authors believe that ongoing and future studies may use this “readily available biomarker” to identify treatment-naive patients with multiple myeloma who might benefit from immunotherapy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.